Difference between revisions of "Renal cell carcinoma, VHL-associated"
Jump to navigation
Jump to search
m |
|||
| Line 21: | Line 21: | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9275515/ Jonasch et al. 2021 (MK-6482-004)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9275515/ Jonasch et al. 2021 (MK-6482-004)] | ||
| − | |2018-2019 | + | {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26" |
| + | |'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-314-1 <span style="color:white;">ESMO-MCBS (3)</span>]''' | ||
| + | |- | ||
| + | |} | ||
| + | |5/31/2018-3/29/2019 | ||
| style="background-color:#91cf61" |Phase 2 (RT) | | style="background-color:#91cf61" |Phase 2 (RT) | ||
|- | |- | ||
Revision as of 13:48, 5 March 2023
Section editor transclusions Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the main RCC page for other regimens.
1 regimens on this page
1 variants on this page
|
All lines of therapy
Belzutifan monotherapy
Regimen
| Study | Years of enrollment | Evidence | |
|---|---|---|---|
Jonasch et al. 2021 (MK-6482-004)
|
5/31/2018-3/29/2019 | Phase 2 (RT) |
References
- MK-6482-004: Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. link to original article contains dosing details in manuscript link to PMC article Pubmed NCT03401788